Substrate access channel topology in membrane-bound prostacyclin synthase

Hui DENG, Aimin HUANG, Shui-Ping SO, Yue-Zhen LIN and Ke-He RUAN

The Vascular Biology Research Center and Division of Hematology, Department of Internal Medicine, The University of Texas Health Science Center, Houston, TX 77030, U.S.A.

Results from our molecular-modelling and site-directed-mutation studies of prostaglandin I₂ synthase (PGIS) have suggested that the large PGIS cytoplasmic domain is anchored to the endoplasmic reticulum (ER) membrane by the N-terminal segment in a way that orients the substrate access channel opening to face the membrane. To test this hypothesis we have explored the accessibility of the PGIS substrate channel opening to site-specific antibodies. The working three-dimensional PGIS model constructed by protein homology modelling was used to predict surface portions near the substrate access channel opening. Two peptides corresponding to the surface immediately near the opening [residues 66–75 (P66–75) and 95–116 (P95–116)], and two other peptides corresponding to the surface about 10–20 Å away from the opening (P66–75 and P95–116), were used to prepare site-specific antibodies. All four antipeptide antibodies specifically recognized the synthetic segments of human PGIS and recombinant PGIS, as shown by binding assays and Western-blot analysis. The site-specific antibodies were used to probe the accessibility of the substrate access channel opening in transiently transfected COS-1 cells expressing recombinant human PGIS, and in spontaneously transformed human endothelial cell line ECV cells expressing endogenous human PGIS. Immunofluorescence staining was performed for cells selectively permeabilized with streptolysin O and for cells whose membranes were permeabilized with detergent. Antibodies to peptides in the immediate vicinity of the substrate channel (P66–75 and P95–116) bound to their targets only after general permeabilization with Triton X-100. In contrast, the two antibodies to peptides further from the channel opening (P366–382 and P472–482) bound to their targets even in cells with intact ER membranes. These observations support our topology model in which the PGIS substrate access channel opening is positioned close to the ER membrane.

Key words: cytochrome P450, membrane topology, peptide antibody, prostaglandin, prostaglandin I₂ synthase

INTRODUCTION

Prostaglandin I₂ synthase (PGIS), a cytochrome P450, contains 500 amino acids with a calculated molecular mass of about 57 kDa [1–3] and is located in the endoplasmic-reticulum (ER) membrane [4–6]. PGIS converts prostaglandin H₂ (PGH₂) into prostaglandin I₂ (PGI₂), a potent inhibitor of platelet aggregation, vasoconstriction and leucocyte interactions with endothelium [7,8]. PGI₂ biosynthesis presumably involves efficient co-ordination in the ER membrane between PGIS and prostaglandin H₂ synthase (PGHS), which produces PGH₂. Results from crystallography and topology studies have indicated that the catalytic domain of PGHS is on the luminal side of the ER, with the cyclooxygenase substrate channel of PGHS immersed in the ER membrane [9–11]. The PGHS lipid substrate, arachidonic acid, thus appears to be delivered to the cyclooxygenase channel via the ER lipid bilayer. PGIS being a member of the microsomal P450 superfamily, its catalytic domain is believed to be anchored to the ER membrane by an N-terminal membrane anchor segment, positioning the PGIS catalytic domain facing the cytoplasmic side of the ER. Our recent peptidoliposome reconstitution and CD spectroscopy studies of the PGIS N-terminal membrane domain concluded that the PGIS N-terminal membrane anchor domain is similar to other microsomal P450s [12]. The PGIS substrate, PGH₂, is thus produced on the ER luminal side and must pass across the ER membrane barrier to reach the catalytic portion of PGIS on the cytoplasmic side. Whether the lipophilic substrate, PGH₂, presents to the synthase directly via the lipid membrane is unknown. The possible models of the substrate access opening of PGIS can be proposed in two ways: (1) facing the ER membrane to receive the hydrophobic substrate directly through the lipid membrane, or (2) exposed on the ER surface to receive the substrate from the aqueous environment (Figure 1). For other microsomal P450s, Nelson and Strobel [13] developed a model for how P450s interact with the membrane, in which the P450 is anchored to the membrane by the N-terminal hydrophobic domain and the Cys-ligand surface predicted to be the main site of interaction with redox partners is oriented away from the membrane, leaving this region available for interaction with the soluble domain of cytochrome P450 (P450) reductase. This orientation places the substrate access opening facing the membrane. Our working models developed for thromboxane A₂ synthase (TXAS) and PGIS by homology modelling strategies using P450, a bacterial P450, as a template, which has a similar substrate-binding cavity [14–16], have indicated that the substrate openings are near the N-terminal membrane-anchor domains. These imply that the substrate access channel openings of PGIS and TXAS face the ER membrane. To test the model, in the present study we have prepared a series of antibodies against the epitopes predicted, by modelling, to be located on the PGIS surface near the opening or on the surface some distance away. These site-specific antibodies
Figure 1  Constructed 3-D structural model of human PGIS based on the P450BM-3 X-ray structure
Four segments with residues 66–75 (magenta), 95–116 (green), 366–382 (blue) and 472–482 (yellow) synthesized for site-specific antibody production are highlighted with ribbons. The red structure denotes haem; the arrow denotes channel opening.

Peptide synthesis
Peptides were synthesized by the solid-phase method using Fmoc (fluoren-9-ylmethoxycarbonyl) chemistry and cleaved with 90 % (w/v) trifluoroacetic acid [18,19]. The peptides were purified to homogeneity using HPLC on a Vydac C18 or C18 reversed-phase column with a gradient of acetonitrile in aqueous trifluoroacetic acid [20,21]. The molecular masses of the purified peptides were verified by using MS [22].

Immunization and characterization of peptide antibodies
Each HPLC-purified peptide was coupled to keyhole-limpet haemocyanin (KLH) using glutaraldehyde [20]. Female New Zealand White rabbits were immunized with 200 µg of peptide–KLH conjugate in Freund’s complete adjuvant; booster immunizations with 200 µg of conjugate in Freund’s incomplete adjuvant were given on days 14, 28 and 48. Blood was collected from the marginal ear vein starting 7 days after the final injection, and IgG fractions were isolated from the resulting antisera by Na2SO4 precipitation and DE52-cellulose ion-exchange chromatography [23]. The antibodies were further purified by affinity chromatography using the appropriate peptide immobilized on CNBr-activated Sepharose 4B [20,24]. Anti-(human PGIS) antibody was obtained from Dr Lee-Ho Wang, Division of Hematology, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, U.S.A. [15].

Cell culture and transfection
Recombinant PGIS was expressed in COS-1 cells as described in [15]. Briefly, COS-1 cells were cultured at 37 °C in a humidified 5 % CO2 atmosphere on a coverslip with Dulbeco’s modified Eagle’s medium containing 10 % (v/v) fetal-calf serum to near confluence (~ 2.5 × 106 cells/dish). The cells were transfected with purified CDNA in the presence of DEAE-dextran and then grown for 48 h before harvesting. Alternatively, intact cells were processed for immunofluorescence staining on the coverslip intended [20]. ECV cells were grown in Medium 199 containing 10 % fetal-calf serum in a humidified 5 % CO2 atmosphere.

Microsome preparation and immunoblotting
The general procedures for microsome preparation and immunoblotting were carried out as described previously [20,25]. The transfected COS-1 cells or ECV cells were scraped from the plates into ice-cold 0.1 M Tris/HCl containing 0.5 mM PMSF and 10 µM indomethacin, pH 7.4, and collected by centrifugation. The pellet was resuspended in the same buffer, sonicated briefly, and centrifuged at 10000 g for 10 min. The supernatant liquid was centrifuged at 200000 g for 40 min to pellet the microsomal fraction, which was resuspended in a small volume of the same buffer. Microsomal proteins were separated by 10 % - (w/v)-PAGE under denaturing conditions and then transferred to a nitrocellulose membrane. Bands recognized by particular primary antibodies were visualized with horseradish peroxidase-conjugated secondary antibody and chromogenic peroxidase substrate [15,20].

Antibody binding assay
Binding of antibody to the corresponding synthetic peptides or the recombinant protein of human PGIS was assessed by enzyme immunoassay as described previously [20].
Indirect immunofluorescence

Procedures used for selective permeabilization of cell membranes were described previously [10,20]. Briefly, ECV cells or transfected COS-1 cells grown on coverslips were washed with 25 mM Hepes, pH 7.4, containing 2.5 mM magnesium acetate, 25 mM KCl and 250 mM sucrose (Hepes buffer) and then incubated at 0 °C (for selective permeabilization of the plasma membrane) or 37 °C (for general permeabilization of plasma and ER membranes) for 10 min with 1.6 units/ml streptolyasin O (SLO), which had been pre-activated with 4 mM dithiothreitol in Hepes buffer at 37 °C for 10 min. After excess toxin was removed by washing twice with Hepes buffer at 0 °C, the cells were incubated at 37 °C for 15 min, fixed with 1% formaldehyde for 10 min, and then blocked with 1% goat serum containing 5 mg/ml glycine in Hepes buffer for 20 min. The fixed cells were then incubated with 10 μg/ml of purified IgG or antisera (1:200 dilution) in Hepes buffer containing 10% goat serum at 24 °C for 1 h. After washing three times with Hepes buffer, the cells were incubated with goat anti-rabbit IgG–FITC conjugate (1:50 dilution, Sigma) in Hepes buffer for 1 h. Washing several times with the sodium-free Hepes buffer, the cells were mounted in Mowiol 4-88 (Calbiochem) containing 2.5% triethylenediamine (Sigma) and protected by a glass coverslip. For alternate general permeabilization, the cells were incubated with 5% Triton X-100 for 20 min, then washed and incubated with the primary and secondary antibodies in the presence of 0.5% Triton X-100 as described above [20]. Cells stained with the FITC conjugate were viewed with an Olympus Model BH-2 epifluorescence microscope.

RESULTS

Design of peptides to probe the accessibility of surfaces near the PGIS substrate access channel

The working 3-D model of PGIS was used to identify surface portions near the substrate access channel opening. The accessibility of the surface regions in the native ER-membrane-bound PGIS provides information about the position of the substrate channel opening relative to the membrane. Two peptides corresponding to the surface immediately near the substrate channel opening [residues 66–75 (P66–75) and 95–116 (P95–116)] and another two peptides predicted to be on the surface about 10–20 Å away from the opening [residues 366–382 (P366–382) and 472–482 (P472–482)] (Figure 1) were selected. The predicted antigenicity and exposure surface of the peptides was checked by hydropathy and secondary-structural analyses using multiple methods. All four peptide segments were predicted to be relatively hydrophilic and to adopt turn structures consistent with predictions from the 3-D working model. The four peptide segments were synthesized, purified, coupled to carrier protein and used to immunize rabbits for production of specific peptide antibodies as described in the Experimental section.

Site-specific antibody purification and characterization

Polyclonal antibodies were fractionated and purified as described in the Experimental section. The purified antibodies were tested for their ability to bind to the target peptide antigens (Figure 2). High titres of antibody binding to cognate peptide were observed for all four site-specific antibodies. In contrast, the pre-immune antibodies did not bind significantly to the target PGIS peptides (Figure 2). The unique binding specificity of the site-directed antibodies was further characterized by enzyme immunoassay using a combination test (Figure 3). The specificity of the antibodies was confirmed by the binding to their target site-specific peptides but not cross-binding to other peptides (Figure 3). Recognition of the site-specific antibodies to the native
Figure 4 Binding of affinity-purified antibodies to recombinant human PGIS protein (upper panel) and Western-blotting analysis of the peptide antibodies binding to human PGIS protein (lower panel)

Upper panel: microtitre-plate wells were coated with 1 μg of octyl glucoside-solubilized recombinant PGIS protein at 4 °C overnight and then incubated with the indicated concentration of the antibodies at 37 °C for 2 h. After washing, bound antibody was quantified as described in the Experimental section. Lower panel: a 60 μg sample of transfected COS-1 cell protein, separated by SDS/10%-w(v)-PAGE, was transferred on to a nitrocellulose membrane. The membrane was probed with individual anti-(peptide P66–75) (lane A), -(peptide P95–116) (lane B), -(peptide P366–382) (lane C) and -(peptide P472–482) (lane D) antibodies (10 μg/ml), which were untreated (lanes A, B, C or D) or pre-incubated with 1 ml of corresponding peptide–Sepharose 4B (1 mg of peptide/1 ml of Sepharose 4B) for 4 h (lanes A(+), B(+), C(+) and D(+) ) or anti-(human PGIS) (lane E) antibody. Lane F is a non-transfected COS-1 cell allowed to react with anti-PGIS antibody. The positions of molecular-mass standards are not shown. The arrow shows the position of PGIS protein. OD 450 nm

Figure 5 Immunofluorescence micrographs of COS-1 cells stained with anti-(PGIS peptide) antibodies

COS-1 cells transfected with human PGIS cDNA were permeabilized with SLO at 0 °C or SLO at 37 °C or Triton X-100. Permeabilized cells were incubated with 10 μg/ml affinity-purified peptide antibody and stained with the FITC-labelled secondary antibody. All photomicrographs were taken with the same exposure times (magnification 500 ×).

Accessibility of target peptides in recombinant PGIS exposed in COS-1 cells

The affinity-purified site-specific peptide antibodies were used as probes to examine the topology of the substrate access channel opening in transiently transfected COS-1 cells expressing recombinant human PGIS. Immunofluorescence staining was performed for cells permeabilized with SLO at 0 °C or 37 °C and for cells whose membranes were disrupted with detergent (Figure 5). SLO treatment at 0 °C was used to selectively permeabilize the plasma membrane without perturbing the ER membrane. SLO treatment at 37 °C was used to permeabilize the plasma and internal membranes and allow the antibodies to reach the luminal side of the ER membrane [10,20]. Triton X-100, a non-ionic detergent, was used to achieve maximal exposure of ER membrane proteins [20]. To confirm that the desired permeabilization was achieved, transfected COS-1 cells permeabilized with the various treatments described above were incubated with rhodamine-labelled phalloidin (targeted at actin in the cytoplasmic compartment) or with antibody to protein disulphide-isomerase (PDI), which is a major ER luminal protein [10,32]. Cells permeabilized with SLO at 0 °C were stained by rhodamine-labelled phalloidin, but were not stained by antibody to PDI. In contrast, the anti-PDI antibody was able to bind its target within the ER lumen only after treatment with SLO at 37 °C or with Triton X-100 (results not shown). These results indicate that
SLO treatment at 0°C selectively breached the plasma membrane, whereas SLO treatment at 37°C or Triton X-100 treatment disrupted both plasma and ER membranes. In addition, Triton X-100-treated cells showed diffuse staining, which reflects that the membrane was solubilized. Antibodies to PGIS peptides in the immediate vicinity of the substrate channel (P66–75 and P95–116) had access to their targets only after the membranes were disrupted with Triton X-100 (Figure 5). In contrast, the antibodies to peptides further from the channel opening (P366–382 and P472–482) had access to their targets, even when cells were treated with SLO at 0°C, a process that leaves ER membranes intact (Figure 5). These observations indicate that the ER membrane-lipid extraction (Triton X-100 treatment) exposes the surface near the PGIS substrate channel opening, whereas toxin-mediated pore formation in the ER membrane (SLO treatment at 37°C) leaves the substrate channel opening region blocked.

**Accessibility of target peptides in endogenous PGIS in ECV cells**

To confirm the immunocytochemical results obtained with recombinant PGIS expressed in COS-1 cells, similar experiments were performed on ECV cells, which have endogenous PGIS (Figure 6). ECV cells were permeabilized with SLO at 0°C or 37°C, or with Triton X-100, incubated with one of the four site-specific peptide antibodies and then stained with FITC-labelled secondary antibody (see the Experimental section for details). Photomicrographs were obtained as described for Figure 5.

![Image](image-url)  
**Figure 6** Immunofluorescence micrographs of ECV cells stained with anti-peptide antibodies

ECV cells were permeabilized with SLO at 0°C or SLO at 37°C or Triton X-100. After reaction with 10 μg/ml affinity-purified peptide antibody, the cells were stained with the FITC-labelled secondary antibody (see the Experimental section for details). Photomicrographs were obtained as described for Figure 5.

**DISCUSSION**

The working 3-D model constructed for PGIS by protein homology modelling was used to identify surface portions near the substrate access channel opening. A crystallographic structure has not been determined for any wild-type mammalian P450. However, a crystallographic structure of the haemoprotein domain of P450<sub>BM-3</sub>, which is considered to be functionally related to microsomal P450s, has been determined at 2.0 Å resolution [26]. The structural similarity of P450<sub>BM-3</sub> to eicosanoid-synthesizing P450s, PGIS and TXAS is reflected in their 25% sequence identity and the substrate similarity. PGH<sub>3</sub>, a substrate for PGIS and TXAS, is derived from arachidonic acid, which is a substrate for P450<sub>BM-3</sub>. The substrate-binding cavities of PGIS and TXAS may therefore have geometric arrangements similar to the substrate-binding pocket of P450<sub>BM-3</sub>. On the basis of the crystallographic structure of the P450<sub>BM-3</sub>zymogen, we had previously constructed a detailed 3-D structural working model of TXAS using the QUANTA-CHARMM protein-modelling package (Molecular Simulations Inc., San Diego, CA, U.S.A.) on a Silicon Graphics (Mountain View, CA, U.S.A.) workstation [14]. The accuracy of the 3-D model has partially been confirmed by site-directed mutagenesis for the several important residues predicted from the 3-D working model, which are involved in the making up of the substrate- or haem-binding sites of TXAS [16]. The observation that the crystallographic structure of P450<sub>BM-3</sub> serves as a suitable template for construction of the 3-D model of TXAS has supported the creation of a 3-D working model for human PGIS (Figure 1) using a protein-modelling process similar to that employed for TXAS. Overall, the conserved helical segments of the haemoprotein domain of P450<sub>BM-3</sub> which have provided the backbone and which have also contributed to important haem- and substrate-binding regions have suggested that the 3-D working model has provided a good approximation to the general folding figure of the substrate-binding channel. A way to evaluate further the accuracy of the general geometric folding of the substrate-binding channel is to identify the key residues that are important in making up the channel, predicted from the working model. Cys<sup>241</sup> and several other residues which are assigned as part of the haem-interaction or substrate-binding pocket from the model have been mutated and confirmed to be important for enzyme activity [15]. These findings have let us use the 3-D working model of human PGIS for the prediction of the opening surface of the substrate-binding channel.

In order to exclude the possibility that the Triton X-100 detergent solubilization may expose an internally buried site to change the protein folding, we have performed a Triton X-100 or octyl glucoside-solubilized PGIS activity assay, in which the synthase activity was not significantly affected by the non-ionic detergents (results not shown). This result supports the fact that detergent-solubilized synthase did not change major protein folding. The immunofluorescent staining for the Triton X-100-treated cells is able to determine the native form of PGIS distributed on the ER membrane.
The peptide antibody staining described in the Results section provides direct experimental evidence to support the model in which the substrate channel opening of PGIS is facing and in contact with the ER membrane. Then the PGIS substrate access surface would be opened and exposed to the lipid bilayer, raising the possibility that the bilayer itself forms part of the access channel. The PGIS lipophilic substrate, PGH$_2$, derived from arachidonic acid by PGHS, would then have ready access to the PGIS active site without even leaving the membrane to contact the polar medium. This is consistent with the results from the studies of the relationship between the ER membrane and the substrate access channel for other P450s using hydrophobic drugs [27,28], and fluorescence energy transfer [29]. Alternative hypotheses can be envisaged, including the possibility of protein–protein interaction. However, it seems unlikely that PGIS interacts with other protein on the epitopes, because the upstream enzyme for PGIS, prostaglandin H$_2$ synthase (PGHS), is located inside the ER membrane (PGIS is located outside the ER membrane) and, unlike other P450 enzymes, PGIS does not require reductase. In addition, it is unlikely that any other protein could cover two independent epitopes of PGIS at one orientation.

Crystallographic studies of detergent-solubilized [9] PGHS-1 and PGHS-2 and topological studies for membrane-bound [10,11] PGHS-1 and -2 suggest that the catalytic domains of the proteins lie on the luminal side of the ER, anchored to the membrane by hydrophobic side chains of amphipathic helices A–D. These hydrophobic side chains of the putative membrane-anchor domains also form an entrance to the substrate-binding channel and potentially form an initial docking site for the lipid substrate, arachidonic acid [9,30]. The topology models developed for PGIS described above have their catalytic domains on the cytoplasmic side of the ER, opposite to the orientation of PGHS, and both of the substrate channels of PGIS and PGHS open to the ER membrane. These suggest that the co-ordination between PGHS and PGIS in biosynthesis of PGH$_2$ is facilitated by the enzyme’s anchoring in the lipid membrane. This predicts that the efficiency of eicosanoid biosynthesis will be different in the soluble and the membrane-bound enzymes. One indication of such a difference has been reported by Eling et al. [31], who found channeling of arachidonic acid through PGG$_2$ to PGH$_2$ in microsomal PGHS, but not in detergent-solubilized PGHS. Another observation, which supports the hypothesis, is that PGHS side-products are much less plentiful in biosynthesis of thromboxane A$_2$ and PGI$_2$ with intact membrane-bound systems as compared with solubilized enzymes. This suggests that the lipid substrates, arachidonic acid and PGH$_2$, have higher-efficiency access to the active sites and less chance to be degraded in the membrane-bound systems.

Characterization of the substrate access channel opening for PGIS described in the present paper also provides general topological information for the important regions of other eicosanoid-synthesizing P450 enzymes, such as TXAS, which shares the same substrate with PGIS. However, TXAS converts PGH$_2$ into thromboxane A$_2$ which is a potent platelet aggregator and vasoconstrictive mediator with biological functions opposite to those of PGI$_2$. Thus the co-ordination of PGHS with TXAS in the biosynthesis of thromboxane A$_2$ may be different to the co-ordination with PGIS. Our previous topological studies have indicated that the large cytoplasmic domain of PGIS is anchored to the ER membrane by a single N-terminal membrane-anchor segment similar to that in other microsomal P450s, but it is quite different from TXAS, which appears to have a longer membrane-anchor segment. It is highly possible that the different N-terminal membrane-anchor format may affect the topological arrangement of the substrate access channel opening for TXAS, which may also be important to the substrate-specific recognition/docking in the co-ordination of PGHS with PGIS or TXAS. Further determination of the topology of the substrate access channel opening for TXAS in native cells will help to address this issue. In addition, the inhibition of binding of substrate-access-site antibodies to a soluble fraction of recombinant PGIS lacking the N-terminal and other possible membrane-anchoring domains would further reinforce the conclusions drawn.

We thank Dr Lee-Ho Wang for providing the PGIS cDNA, and Dr Richard J. Kulmacz and Dr Kenneth K. Wu for valuable discussions while these studies were in progress. This work was supported by National Institute of Health grants (HL56712 and NS 23327).

REFERENCES


© 2002 Biochemical Society


Received 29 April 2001/14 November 2001; accepted 13 December 2001